Baxter International

Baxter’s moat is based on: 1) switching costs in infusion ecosystems where hospitals standardize on pumps, sets, software, and connectivity; 2) efficient scale and manufacturing expertise in sterile IV solutions; and 3) a broad installed base from Hillrom assets (beds, patient monitoring, connectivity) that creates multi‑product relationships.

These factors historically yielded sticky revenue and cross‑selling.

However, two developments dilute durability: the FDA’s Class I recall communications and corrective actions for the Novum IQ large‑volume pump, including external reports of two deaths and 79 serious injuries, and Baxter’s temporary pause of shipments; and the hurricane exposure of concentration risk at North Cove for IV solutions.

In infusion, BD’s Alaris is back with 510(k) clearance, and though BD also faces set‑related recalls, competitive intensity rises. Baxter retains credible scale and routes to market, but the added quality and single‑site risks lower the sustainability of advantage over the next decade.